Marker Therapeutics, Inc.

Monthly Archives: July 2015

TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications

Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials

SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, is pleased to announce that the Company has exercised its option agreement with Mayo Clinic.

Read More